Abatacept reduces acute GVHD (aGVHD) without increasing relapse and infections. The article from Takahashi et al demonstrates a strong correlation between efficacy (aGVHD reduction) and abatacept exposure but not with relapse and infections. APC, antigen-presenting cell; MHC-TCR, major histocompatibility complex-T-cell receptor.